论文部分内容阅读
目的探讨紫杉醇联合卡铂治疗非小细胞肺癌的临床疗效。方法选取2010年2月～2012年2月来本院治疗的非小细胞肺癌患者80例,将其随机分为观察组和对照组各40例,对照组采用顺铂进行治疗,观察组采用紫杉醇联合卡铂进行治疗,比较两组的临床治疗效果及毒副反应。结果疗程结束后观察组有效率为90.0%,高于对照组的77.5%,两组差异有统计学意义(P<0.05)。观察组主要不良反应为变态反应、骨髓抑制、胃肠道反应,对照组无明显毒副反应。结论紫杉醇联合卡铂治疗非小细胞肺癌疗效显著,不良反应轻微,安全、有效,值得临床推广使用。
Objective To investigate the clinical efficacy of paclitaxel combined with carboplatin in the treatment of non-small cell lung cancer. Methods Eighty patients with non-small cell lung cancer who were treated in our hospital from February 2010 to February 2012 were randomly divided into observation group (40 cases) and control group (40 cases). Patients in the control group were treated with cisplatin. The observation group was treated with paclitaxel Combined carboplatin for treatment, comparing the clinical efficacy of the two groups and side effects. Results The effective rate of the observation group after the course of treatment was 90.0%, which was higher than that of the control group (77.5%). The difference between the two groups was statistically significant (P <0.05). The main adverse reactions in the observation group were allergic reaction, myelosuppression, gastrointestinal reaction and no obvious side effects in the control group. Conclusion paclitaxel combined with carboplatin in the treatment of non-small cell lung cancer has obvious curative effect, minor adverse reactions, safe and effective, worthy of clinical promotion and use.